Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

121
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
121
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

909
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
909
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

338
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
338
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

112
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
112
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

250
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
250
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

70
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
70

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

The protein kinase DYRK1B is a p53 target gene and functions as a negative feedback regulator of the transcription factor RFX7.

Cell death & disease·2026
Same author

The quantitative impact of metabolism-inhibiting drugs on the occurrence of adverse drug reactions-A backward selection approach.

British journal of clinical pharmacology·2026
Same author

The Key Role of Personality Functioning in Understanding the Link Between Adverse Childhood Experiences and Loneliness: A Cross-Sectional Mediation Analysis.

Brain sciences·2025
Same author

Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study.

Clinical pharmacology and therapeutics·2025
Same author

Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants.

Pharmacogenomics·2025

Related Experiment Video

Updated: Aug 16, 2025

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes.

Julia Carolin Stingl1, Jason Radermacher1, Justyna Wozniak1

  • 1Institute of Clinical Pharmacology, University Hospital of RWTH, 52074 Aachen, Germany.

Pharmaceutics
|December 23, 2022
PubMed
Summary
This summary is machine-generated.

Pharmacogenetic variability impacts drug efficacy and safety. This study introduces a statistical method for precise psychotropic drug dose adjustments in specific genetic groups, improving patient outcomes.

Keywords:
CYP2C19cytochrome P450 enzymesdose adjustmentdrug metabolismhorseshoepharmacogeneticsrandom effectsshrinkage

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K

Related Experiment Videos

Last Updated: Aug 16, 2025

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K

Area of Science:

  • Pharmacogenetics
  • Statistical Modeling
  • Drug Metabolism

Background:

  • Patient response to drugs varies due to genetic differences in drug metabolism.
  • Existing methods for dose adjustment lack precision, especially with limited data.
  • Cytochrome P450 enzymes, like CYP2C19, play a key role in drug metabolism.

Purpose of the Study:

  • To develop a systematic statistical methodology for quantitative dose adjustments.
  • To address challenges like sparse data, incomplete phenotypic information, and study design heterogeneity.
  • To provide reliable dose adjustments for psychotropic medications based on pharmacogenetic subgroups.

Main Methods:

  • Utilized psychotropic drugs metabolized by CYP2C19 as a case study.
  • Estimated CYP2C19 activity scores and assessed methodological influences on study data.
  • Employed Bayesian approaches, specifically the regularized horseshoe, for robust coefficient estimation and dose adjustment predictions.
  • Compared the regularized horseshoe to traditional fixed-effects and weighted-mean approaches.

Main Results:

  • The regularized horseshoe approach provided conservative and sensitive dose adjustment estimates, particularly with small study sizes.
  • Statistical modeling effectively assessed study parameter influences and extrapolated dose adjustments across phenotype groups.
  • The methodology successfully predicted dose adjustments with limited data through a 'shrinkage' effect.
  • Bayesian modeling offered a more robust estimation of dose adjustments compared to traditional methods.

Conclusions:

  • A novel Bayesian statistical methodology enables accurate, quantitative dose adjustments for psychotropic drugs based on pharmacogenetics.
  • This approach enhances drug safety and efficacy by accounting for individual metabolic variability.
  • The regularized horseshoe method offers a powerful tool for handling sparse data and heterogeneity in pharmacogenetic studies.
  • This systematic approach improves personalized medicine by providing reliable dose recommendations and uncertainty levels.